Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05929222 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Study acronym: FIL_GAZEBO
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 4 of 49 sitesv10
  2. Study sites: 48 to 49v9
  3. Site details revised at 5 of 48 sitesv8
  4. Site details revised at 10 of 48 sites
    • Collaborators shortened, about 3 words
    v7
  5. Site details revised at 18 of 48 sitesv6
Show 4 earlier versionsHide 4 earlier versions
  1. Site details revised at 6 of 48 sitesv5
  2. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Start date changed from estimate of Jan 2024 to Dec 14, 2023
    • Interventions: Radiotherapy (Radiation), Radiotherapy plus Obinotuzumab (Other) to Radiotherapy (Radiation), Radiotherapy plus Obinutuzumab (Other)
    • Study description revised
    • Site details revised at 48 of 48 sites
  3. Start date: Sep 2023 to Jan 2024v3 Show 4 more changesShow less
    • Primary and study completion dates: Dec 2030 to Apr 2031
    • Eligibility criteria shortened, about 74 words
    • Secondary endpoints: 15 to 14
    • Study description shortened, about 19 words
  4. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Prospective, multicenter, open label, phase III randomized clinical trial in previously untreated Follicular Lymphoma in early stage. Patients will be randomized to receive Radiotherapy or Radiotherapy plus Obinutuzumab.
Trial Details
NCT Number NCT05929222
Lead Sponsor Fondazione Italiana Linfomi - ETS
Conditions
(from sponsor)		 Follicular Lymphoma
Related terms Lymphoma, Lymphoma, Follicular, Neoplasm, Residual
Enrollment 190 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov